Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib

• DOI: 10.1200/jco.2008.26.15_suppl.8035
• Publication Date: 2017-02-24T07:33:44Z
• Authors: D. M. Jackman; L. V. Sequist; L. Cioffredi; M. Gallegos Ruiz; P. A. Janne; G. Giaccone; V. A. Miller; B. E. Johnson
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

8035 Background: There is increasing interest in the impact of EGFR and KRAS genotype on patterns response resistance NSCLC pts treated with gefitinib or erlotinib. We created a mutation registry to track protocol-based clinical outcomes specific mutations initially an EGFR-TKI. Methods: To date, 5 trials performed US Europe have been included this registry. These include: 1) erlotinib age > 70 yrs; 2) unselected pts; 3) known mutations; 4) bronchioloalveolar carcinoma (BAC) adenocarcinoma BAC features; 5) for women who were former never smokers. The includes only chemo-naïve pts, assess EGFR-TKI’s tumors that not exposed effects cytotoxic chemotherapy. Results: 290 previously untreated enrolled these from 2003 until present. 277 chemo-naive tested mutations, 180 mutations. A total 121 detected. 75 had sensitizing mutation. (RR = 63%, median PFS=11.4 m, OS=23.8 m). Pts exon 19 deletions prolonged TTP (13.0 vs 9.7 m) OS (30.8 14.8 compared L858R In found there was no correlation between either smoking status, gender, type EGFR-TKI administered (erlotinib gefitinib). 20 insertions, T790M associated therapy. responses group. For 40 alone, progression-free survival 3.3 months; overall 13.0 months. Conclusions: important predicting treatment creation central may help yield more powerful insight into roles other guide decisions. Author Disclosure Employment Leadership Consultant Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca, Boehringer Ingelheim, Genentech, Genzyme, Roche Pfizer MolecularMD